To determine the biological role of gut microbiota in regulating patients’ response to ICB therapy, Davar et al., evaluated the therapeutic efficiency of combined treatment of FMT (from PD-1 responders) and anti-PD-1 administration on patients with PD-1 refractory melanoma (82). The gene discussed is PDCD1; the disease is melanoma.